her2 breast cancer

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination Accurately determining HER2 status in patients with breast cancer is a critical prognostic and predictive factor and identifies patients who Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy Brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond — and which should switch to another kind of Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence.


One metastatic breast cancer. At a recent conference, researchers from the Institute of Research in London explain how a drug combination worked to dramatically shrink Study demonstrates value of new measurement reference for both evaluating assay performance and increasing confidence in reporting HER2 amplification Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune.

HER2 Guidelines for Breast Cancer Could Misclassify Some Patients - Cancer Network
Targeted OncologyHER2 Guidelines for Breast Cancer Could Misclassify Some PatientsCancer NetworkThe 2013/2014 American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment. These results were presented Patients Liable to Be Misclassified Under New HER2 Gene Testing Guidelines, Expert SaysTargeted OncologyDr. Osborne Discusses the Future of Treatment in HER2+ Breast CancerOncLiveNeoadjuvant Treatment Options May Improve Chances of Breast ConservationCuretoday.comCancer Therapy Advisor -Diabetes.co.ukall 40 news articles »

Dr. Janni on Reducing Adverse Events of HER2-Targeted Treatment in Breast Cancer - OncLive
OncLiveDr. Janni on Reducing Adverse Events of HER2-Targeted Treatment in Breast CancerOncLiveWolfgang Janni, MD, PhD, University of Ulm, discusses the management of adverse events for patients being treated with HER2-targeted therapies. The benefits of HER2-targeted therapies outweigh the adverse events associated with them, says Janni.

Findings From the SystHERs Real-World Study of HER2+ Breast Cancer - OncLive
OncLiveFindings From the SystHERs Real-World Study of HER2+ Breast CancerOncLiveThe publicly reported results of the ongoing SystHERs study in HER2-positive breast cancer were discussed at the 2017 Miami Breast Cancer Conference by Mohammad Jahanzeb, MD, medical director of Sylvester Comprehensive Cancer Center and Brain metastases in newly diagnosed breast cancer patients profiledmedwireNewsHER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025Medgadget (blog)11 years follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancerPharmacy Today, American Pharmacists Association, pharmacist.comall 4 news articles »

HER2-Negative Breast Cancer Treatment Market Set to Witness an - Medgadget (blog)
OncLiveHER2-Negative Breast Cancer Treatment Market Set to Witness an Medgadget (blog)Group of diseases that tend to mutate the cells in the body resulting into uncontrolled division of cells forming a mass or lump called as tumor. Cancer is.Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast CancerOncLiveall 6 news articles »

HER2-Negative Breast Cancer Treatment Market to Witness a Pronounce Growth During 2017 – 2025 : Persistence - Medgadget (blog)
HER2-Negative Breast Cancer Treatment Market to Witness a Pronounce Growth During 2017 – 2025 : Persistence Medgadget (blog)Group of diseases that tend to mutate the cells in the body resulting into uncontrolled division of cells forming a mass or lump called as tumor. Cancer is generally named after the body part from where the tumor originates. The breast cancer

Advancements Continue in HER2-Positive Breast Cancer - Curetoday.com
Curetoday.comAdvancements Continue in HER2-Positive Breast CancerCuretoday.comHow far have we come in treating HER2-positive metastatic breast cancer? In terms of the metastatic setting, we have many different treatment options available now for patients. Just 10 years ago, when I started as a breast oncologist out of my HER2-Negative Breast Cancer Treatment Market Set to Witness an Uptick During 2017- 2025 : Persistence Market Medgadget (blog)Dr. Jahanzeb on the Future of Adjuvant Therapy in HER2+ Breast CancerOncLiveShorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved ResultsOncology Nurse AdvisorNottingham Post -HospiMedica (registration)all 11 news articles »

HER2-Targeted Therapy in Early Stage HER2+ Breast Cancer - OncLive
OncLiveHER2-Targeted Therapy in Early Stage HER2+ Breast CancerOncLivePanelists: Adam M. Brufsky, MD, PhD, University of Pittsburgh School of Medicine; Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center; Aditya Bardia, MD, MPH, Massachusetts General Hospital Cancer Center; Kimberly L. Blackwell, MD, Duke and more »

Overcoming Resistance to HER2-Targeted Therapy in Breast Cancer - OncLive
OncLiveOvercoming Resistance to HER2-Targeted Therapy in Breast CancerOncLiveThere are several proposed mechanisms of resistance being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer. The strengthening of antibody dependent cell-mediated cytotoxicity (ADCC) shows promise in clinical trials, 

Some Breast Cancer Patients May Be Misclassified, Expert Explains - Curetoday.com
Curetoday.comSome Breast Cancer Patients May Be Misclassified, Expert ExplainsCuretoday.comPress, the Harold E. Lee Chair for Cancer Research in the Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, discussed the new ASCO-CAP guidelines for HER2 FISH testing at the 2017 Miami Breast Cancer FDA Approves Ribociclib for Frontline HR+/HER2- Breast CancerOncLiveFDA Approves First-Line Combo Treatment for HR+/HER2- Metastatic Breast CancerPharmacy TimesKisqali Approved as First-Line Therapy for HR+/HER2-Metastatic Breast CancerPharmacy Practice NewsAJMC.com Managed Markets Network -Pharmacy Today, American Pharmacists Association, pharmacist.com -Novartisall 104 news articles »

A New Treatment Destroyed Breast Cancer Tumors in 11 Days - Futurism
FuturismA New Treatment Destroyed Breast Cancer Tumors in 11 Days FuturismA new clinical trial demonstrated positive effects caused by the drug combination lapatinib and trastuzumab against HER2 positive breast cancer in a treatment Expert Explores Most Effective Use of Immunotherapy in Breast CancerTargeted Oncologyall 15 news articles »

Your name (required)
Your e-mail (required)